{"id":"W4388816741","doi":"10.1016/j.jocn.2023.11.013","title":"Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Neuroscience","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Montreal Neurological Institute and Hospital","funders":"Novartis Institutes for BioMedical Research; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Myasthenia gravis; Monoclonal antibody; Antibody; Internal medicine; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002146945,0.001539527,0.003402776,0.0004682435,0.0004881237,0.001271867,0.0008278448,0.001777819,0.003127462],"category_scores_gemma":[0.00155405,0.0005941047,0.001915408,0.0004860995,0.001478083,0.001152153,0.0003175209,0.002749771,0.0005139298],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007862714,"about_ca_system_score_gemma":0.0009565167,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000756391,"about_ca_topic_score_gemma":0.001266478,"domain_scores_codex":[0.9991264,0.0004810262,0.00004637718,0.0001168987,0.00007440385,0.00015498],"domain_scores_gemma":[0.9987992,0.0003484541,0.0002178708,0.00008490467,0.00008236301,0.0004671902],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9640425,0.008173548,0.001334527,0.0004872379,0.001143045,0.00005728563,0.00005997817,0.0006191143,0.004693461,0.000127144,0.0006568695,0.01860534],"study_design_scores_gemma":[0.8016502,0.1907556,0.004395664,0.00003657084,0.0008722821,0.00008951867,0.00003322131,0.0006173396,0.0006601584,0.0001949698,0.0006672729,0.00002719415],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931266,0.003486518,0.0003864908,0.000283644,0.000172709,0.0008365787,0.0004274707,0.00003923722,0.001240687],"genre_scores_gemma":[0.9943836,0.001508244,0.0005931996,0.0005526446,0.0002955556,0.0009183033,0.0006450783,0.00001464284,0.001088843],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003402776,"threshold_uncertainty_score":0.01135427,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08698101969012068,"score_gpt":0.4553612079200692,"score_spread":0.3683801882299485,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}